Kevin Fitzgerald Net Worth

The estimated Net Worth of Kevin Joseph Fitzgerald is at least $9.62 million dollars as of 12 August 2024. Kevin Fitzgerald owns over 22,025 units of Alnylam Pharmaceuticals Inc stock worth over $3,373,663 and over the last 3 years he sold ALNY stock worth over $6,245,281. In addition, he makes $0 as Senior Vice President et Chief Scientific Officer at Alnylam Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kevin Fitzgerald ALNY stock SEC Form 4 insiders trading

Kevin has made over 2 trades of the Alnylam Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 22,025 units of ALNY stock worth $5,968,555 on 12 August 2024.

The largest trade he's ever made was selling 22,025 units of Alnylam Pharmaceuticals Inc stock on 12 August 2024 worth over $5,968,555. On average, Kevin trades about 3,871 units every 8 days since 2021. As of 12 August 2024 he still owns at least 12,881 units of Alnylam Pharmaceuticals Inc stock.

You can see the complete history of Kevin Fitzgerald stock trades at the bottom of the page.

Kevin Fitzgerald biography

Dr. Kevin Fitzgerald is Senior Vice President, Chief Scientific Officer of the company. Dr. Fitzgerald will be responsible for the strategic direction and oversight of Alnylam's discovery engine. He has over 20 years of experience in the context of small molecule and oligonucleotide drug discovery. Dr. Fitzgerald's tenure at Alnylam began in 2005 when he joined as an Associate Director of Research. He has headed the Research department since 2016. His achievements include leadership of Alnylam's RNAi delivery efforts, resulting in two clinically validated modes of siRNA delivery, as well as the development of the Company's comprehensive clinical pipeline. He is an inventor on over 50 patents that apply to the majority of Alnylam's pipeline programs, and the author of over 40 manuscripts, including many in prestigious journals such as Nature, Cell , and The New England Journal of Medicine . Kevin has led or supported multiple programs from discovery through various stages of clinical development. Kevin received his Bachelor of Science in Genetics from Cornell University and his doctorate in Molecular Biology from Princeton University. He completed his post-doctoral fellowship at Harvard Medical School.

What's Kevin Fitzgerald's mailing address?

Kevin's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal et Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.

What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Complete history of Kevin Fitzgerald stock trades at Alnylam Pharmaceuticals Inc et Ovid Therapeutics Inc

Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Maraganore,
  Chief Executive Officer, Director
• Jeffrey Poulton,
  Chief Financial Officer, Executive Vice President
• Laurie Keating,
  Executive Vice President, Chief Legal Officer, Secretary
• Yvonne Greenstreet,
  President, Chief Operating Officer
• Akshay Vaishnaw,
  President - Research and Development
• Dr. John M. Maraganore M.D., Ph.D.,
  CEO & Exec. Director
• Margaret Hamburg,
  Independent Director
• Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB,
  Pres, COO & Director
• Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA,
  Pres & COO
• Dr. Akshay K. Vaishnaw,
  Pres of R&D
• Jeffrey V. Poulton M.B.A.,
  CFO & Exec. VP
• Laurie Bartlett Keating J.D.,
  Exec. VP, Chief Legal Officer & Sec.
• Michael Bonney,
  Independent Chairman of the Board
• Phillip Sharp,
  Independent Director
• Marsha Fanucci,
  Independent Director
• Amy Schulman,
  Independent Director
• Steven Paul,
  Independent Director
• Colleen Reitan,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Michael W. Bonney B.A.,
  Exec. Chairman
• Olivier Brandicourt,
  Director
• Kevin Fitzgerald,
  Senior Vice President, Chief Scientific Officer
• Kelley Boucher,
  Chief Human Resource Officer, Senior Vice President
• Arianna Greco,
  Interim Chief Legal officer
• Mark Baglin,
  VP of Global Marketing
• Agnieszka Gallagher,
  Chief Ethics & Compliance Officer
• Christine Regan Lindenboom,
  Sr. VP of Investor Relations & Corp. Communications
• Dr. Alfred W. Boyle Ph.D.,
  Chief Technical Operations & Quality Officer
• David Alexandre C Gros,
  SVP, Chief Business Officer
• Kevin P Starr,
  Director
• Paul Schimmel,
  Director
• Sanofi,
  10% owner
• Michael Mason,
  VP, Finance and Treasurer
• John K Clarke,
  Director
• Barry E Greene,
  President
• Manmeet Singh Soni,
  Chief Financial Officer
• Carolyn R Bertozzi,
  Director
• Pushkal Garg,
  CMO & EVP Dev & Med Affairs
• Peter N Kellogg,
  Director
• Venture Management Co Iii L...,
  10% owner
• Victor J Dzau,
  Director
• Agnovartis Pharma Ag Novartis,
  
• Venture Management Co Iii L...,
  
• Peter Barrett,
  Director
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Ii Lp Chp,
  10% owner
• Kenneth S Koblan,
  Chief Scientific Officer
• Laurence Reid,
  SVP, Chief Business Officer
• Vicki L Sato,
  Director
• Management Ltd Abingworth,
  10% owner
• John A Jr Schmidt,
  SVP, Chief Scientific Officer
• Patricia L Allen,
  VP Finance and Treasurer
• Venture Fund V Lpatlas Vent...,
  
• John E Berriman,
  Director
• Vincent J Miles,
  Senior VP Business Development
• James L Vincent,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Edward M Scolnick,
  Director
• Tolga Tanguler,
  EVP, Chief Commercial Officer
• Charles Elliott Sigal,
  Director